BioLineRx (BLRX)
BioLineRx Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these BLRX related companies
BLRX News
BioLineRx to Present at the 2012 Annual Needham Healthcare Conference in New York on April 3rd
Mar 28, 7:00AM Business Wire
Mar 28, 7:00AM Business Wire
BioLineRx to Present at the 2012 Annual Roth Growth Conference in Orange County, California on March 14th
Mar 07, 9:00AM Business Wire
Mar 07, 9:00AM Business Wire
BioLineRx Announces Grant of European Patent Covering BL-1020, an Orally Available Treatment for Schizophrenia
Mar 07, 6:00AM Business Wire
Mar 07, 6:00AM Business Wire
BioLineRx (BLRX) Files 5.24M ADS, 2.62M Warrant Shelf for Shareholders
Mar 01, 2:56PM Street Insider
Mar 01, 2:56PM Street Insider
BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BCM
Feb 29, 7:05AM Benzinga
Feb 29, 7:05AM Benzinga
BioLineRx Ltd. Announces Closing of $15 Million Private Placement to Institutional Investors
Feb 27, 5:00PM Business Wire
Feb 27, 5:00PM Business Wire
BioLineRx (BLRX) Reports Pre-Clinical Results Demonstrating Efficacy of BL-7010
Feb 21, 7:15AM Street Insider
Feb 21, 7:15AM Street Insider
BioLineRx Ltd. (BLRX) Surges on Second Hep-C Play, Traders Raise Eyebrows
Feb 06, 9:46AM Street Insider
Feb 06, 9:46AM Street Insider
BioLineRx (BLRX) Enters Global Development, License Agreement for HCV Treatment BL-8030
Feb 06, 6:49AM Street Insider
Feb 06, 6:49AM Street Insider
BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C
Jan 24, 7:00AM Benzinga
Jan 24, 7:00AM Benzinga
BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen
Dec 13, 6:53AM Benzinga
Dec 13, 6:53AM Benzinga
BioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of BL-1021 for Neuropathic Pain
Dec 06, 7:00AM Business Wire
Dec 06, 7:00AM Business Wire
BioLineRx announces India approval to start Clarity phase 2/3 clinical trial
Nov 22, 7:02AM FlyOnTheWall
Nov 22, 7:02AM FlyOnTheWall
BioLineRx retains KCSA Strategic Communications for investor relations program
Sep 22, 8:17AM FlyOnTheWall
Sep 22, 8:17AM FlyOnTheWall
BioLineRx Ltd. Retains KCSA Strategic Communications as U.S. Investor Relations Counsel
Sep 22, 8:00AM PR Newswire
Sep 22, 8:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BLRX | 2.51 | -0.03 | -1.18% | 31.02M |
| BLL | 39.88 | +0.02 | +0.05% | 6.235B |
| BLKB | 26.30 | -0.04 | -0.15% | 1.182B |
| BLK | 171.36 | +0.92 | +0.54% | 23.88B |
| BLIN | 1.46 | -0.02 | -1.35% | 18.22M |
| BLH | 17.04 | +0.11 | +0.68% | |
| BLDR | 3.97 | -0.06 | -1.49% | 383.54M |
| BLDP | 1.16 | +0.02 | +1.75% | 97.85M |
| BITS | 4.32 | +0.00 | +0.00% | 45.92M |
| BITA | 3.98 | -0.01 | -0.25% | 165.73M |
